Sign In
Buy SRDX
$42.98
+0 (+0%)
At Close: Feb 24, 2026
Here's What Key Metrics Tell Us About SurModics (SRDX) Q3 Earnings
11:30am, Wednesday, 31'st Jul 2024
Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street
SurModics (SRDX) Reports Q3 Loss, Tops Revenue Estimates
09:21am, Wednesday, 31'st Jul 2024
SurModics (SRDX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.52 per share a year ago.
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. – SRDX
02:56pm, Monday, 08'th Jul 2024
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. - SRDX
03:02pm, Wednesday, 03'rd Jul 2024
NEW YORK , July 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securiti
Surmodics (SRDX) Inks Group Purchasing Agreement With Premier
11:41am, Tuesday, 11'th Jun 2024
Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier.
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
07:00am, Monday, 10'th Jun 2024
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing
Why Is SurModics (SRDX) Up 21.9% Since Last Earnings Report?
12:35pm, Friday, 31'st May 2024
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M
12:31pm, Friday, 31'st May 2024
Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.
NEW ORLEANS, LA / ACCESSWIRE / May 30, 2024 / Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc.
06:36pm, Wednesday, 29'th May 2024
NEW YORK , May 29, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Surmodics, Inc. (NASDAQ: SRDX) and its board of directors concerning the proposed acquis
Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals
11:55am, Wednesday, 29'th May 2024
Merck and Surmodics announced big takeover deals Wednesday, but Merck stock remained at a standstill as Surmodics stock rocketed.
Shareholder Alert: Ademi LLP investigates whether Surmodics, Inc. has obtained a Fair Price for its Public Shareholders
10:45am, Wednesday, 29'th May 2024
MILWAUKEE , May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Surmodics (Nasdaq: SRDX) for possible breaches of fiduciary duty and other violations of law in its transaction with GTCR. Click h
SRDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surmodics, Inc. Is Fair to Shareholders
08:16am, Wednesday, 29'th May 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Surmodics, Inc. (NASDAQ: SRDX) to GTCR for $43.00 per share in cash is fair to Surmodics
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
11:50am, Monday, 20'th May 2024
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
